These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17872866)

  • 1. Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? No.
    Aaron SD
    Can Fam Physician; 2007 Sep; 53(9):1429-30, 1432. PubMed ID: 17872866
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? Yes.
    Salpeter SR
    Can Fam Physician; 2007 Sep; 53(9):1429-30, 1432-3. PubMed ID: 17872865
    [No Abstract]   [Full Text] [Related]  

  • 3. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for chronic obstructive pulmonary disease: possible confounding effect of treatment withdrawal?
    Brown SM
    Ann Intern Med; 2007 Dec; 147(12):882; author reply 882-3. PubMed ID: 18087061
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? NO.
    Aaron SD
    Can Fam Physician; 2007 Aug; 53(8):1290-2, 1294-7. PubMed ID: 17872839
    [No Abstract]   [Full Text] [Related]  

  • 5. Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES.
    Salpeter SR
    Can Fam Physician; 2007 Aug; 53(8):1290-7. PubMed ID: 17872838
    [No Abstract]   [Full Text] [Related]  

  • 6. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.
    Matera MG; Caputi M; Cazzola M
    Respir Med; 1996 Sep; 90(8):497-9. PubMed ID: 8869445
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study].
    Seeger W; Schulz R
    Internist (Berl); 2004 Jun; 45(6):727-8. PubMed ID: 15138641
    [No Abstract]   [Full Text] [Related]  

  • 10. A word of caution regarding a new long-acting bronchodilator.
    Bone RC
    JAMA; 1994 May; 271(18):1447-8. PubMed ID: 7909854
    [No Abstract]   [Full Text] [Related]  

  • 11. Salmeterol xinafoate vs albuterol in asthma: was race a factor?
    Olopade CO
    JAMA; 1994 Nov 23-30; 272(20):1576. PubMed ID: 7966862
    [No Abstract]   [Full Text] [Related]  

  • 12. Breathlessness during exercise in COPD: how do the drugs work?
    Calverley PM
    Thorax; 2004 Jun; 59(6):455-7. PubMed ID: 15170021
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD.
    Cazzola M; Matera MG
    Pulm Pharmacol Ther; 2003; 16(4):197-201. PubMed ID: 12850121
    [No Abstract]   [Full Text] [Related]  

  • 14. Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    Miller FG; Shorr AF
    JAMA; 2001 Dec; 286(24):3075-6; author reply 3077-8. PubMed ID: 11754663
    [No Abstract]   [Full Text] [Related]  

  • 15. Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    Fowler SJ; Lipworth BJ
    JAMA; 2001 Dec; 286(24):3076-7; author reply 3077-8. PubMed ID: 11754665
    [No Abstract]   [Full Text] [Related]  

  • 16. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
    Gillissen A
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    Botkin JR; Clayton E; Nelson R; Wilfond B; Munger MA
    JAMA; 2001 Dec; 286(24):3075; author reply 3077-8. PubMed ID: 11754662
    [No Abstract]   [Full Text] [Related]  

  • 19. Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    Friedman Ross L
    JAMA; 2001 Dec; 286(24):3076; author reply 3077-8. PubMed ID: 11754664
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.